Indegene Limited
Indegene Limited operates in Healthcare Research, Analytics & Technology, part of the Healthcare sector. It booked ₹1,122 cr of revenue in its latest quarter (Q2 FY27) and kept 10.0% of sales as profit. It is the 2nd largest of 5 Healthcare Research, Analytics & Technology companies we track, by market value.
| Segment | FY25 | FY26 | Share |
|---|---|---|---|
| Enterprise Commercial Solutions | 1,587 | 2,461 | 56% → 70% |
| Enterprise Medical Solutions | 803 | 930 | 28% → 26% |
| Others | 102 | 120 | 4% → 3% |
| Omnichannel Activation | 348 | — | — |
| Total | 2,839 | 3,511 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
Healthier than 73% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 16–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 57
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in INDGN?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 10%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹1,122 cr |
| Other Income | ₹15 cr |
| Total Income | ₹1,137 cr |
| Cost of Materials | ₹0 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Employee Benefit Expense | ₹682 cr |
| Finance Costs | ₹7 cr |
| Depreciation & Amortisation | ₹46 cr |
| Other Expenses | ₹255 cr |
| Total Expenses | ₹990 cr |
| Profit before Tax | ₹147 cr |
| Tax Expense | ₹35 cr |
| Net Profit | ₹112 cr |
| Net margin on total income | 9.9% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 1,003 cr | 1,063 cr | 1,122 cr |
| Total income | 1,014 cr | 1,092 cr | 1,137 cr |
| Expenses | 889 cr | 939 cr | 990 cr |
| Profit before tax | 105 cr | 153 cr | 147 cr |
| Tax | 25 cr | 37 cr | 35 cr |
| Net profit (owners' share) | 80 cr | 116 cr | 112 cr |
| Net margin (owners' share, on revenue) | 7.9% | 10.9% | 10.0% |
| EPS (₹) | 3.32 | 4.84 | 4.67 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Syngene International Limited | ₹407 | ₹16,414 cr | 127.1 | 2.7% | 3.9% | — |
| Indegene Limitedthis company | ₹613 | ₹14,738 cr | 32.8 | 13.4% | 10.0% | — |
| Suven Life Sciences Limited | ₹261 | ₹6,895 cr | — | -86.3% | — | — |
| Vimta Labs Limited | ₹486 | ₹1,079 cr | 15.4 | 25.1% | 23.9% | — |
| TAKE Limited | ₹11 | ₹161 cr | 38.9 | 13.7% | 3.5% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹2.25 / share | 31 Jul 2026 |
| Dividend | ₹2 / share | 13 Jun 2025 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.
The company has not broken this money down into purposes in its filing for Mar 2025, so there is nothing to measure it against yet. CARE Ratings Limited watches the spending on the exchange’s behalf.
Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing